Schedule III [21 CFR 1308.13]
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Source: DEA Office of Diversion Control: Section 1308: Schedules of Controlled Substances
(b)
Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous sxstem[sic], including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
Effective 7 Jul 1971, 36 FR 12734 revoked (and renumbered subsequent entries):
On 26 May 1971, 36 FR 9563 proposed to revoke (and to renumber subsequent entries:)
Amphetamine, its salts, optical isomers, and salts of its optical isomers.
US: Currently at CSA Schedule II Section d Subsection 1 Amphetamine
Effective 28 Oct 1971, 36 FR 20686 revoked (and renumbered subsequent entries):
Phenmetrazine and its salts.
US: Currently at CSA Schedule II Section d Subsection 3 Phenmetrazine
Effective 7 Jul 1971, 36 FR 12734 revoked (and renumbered subsequent entries):
On 26 May 1971, 36 FR 9563 proposed to revoke (and to renumber subsequent entries:)
Any substance (except an injectable liquid) which contains any quantity of Methamphetamine, including its salts, isomers, and salts of isomers.
US: Currently at CSA Schedule II Section d Subsection 2 Methamphetamine
Effective 28 Oct 1971, 36 FR 20686 revoked (and renumbered subsequent entries):
Methylphenidate
US: Currently at CSA Schedule II Section d Subsection 4 Methylphenidate
(1)
1405
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Sec. 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances
Effective 31 Dec 1969, replacement for:
Effective 15 Jun 1973, 38 FR 15719 replacement for:
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under §308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances.
On 26 May 1971, 36 FR 9563 proposed to add:
Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances which are currently listed as exected compounds under 21 CFR 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances.
Effective 7 Jul 1971, 36 FR 12734 added:
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12119 proposed to add:
(2)
1228
Benzphetamine
CA: CDSA Schedule I Section 19 Subsection 17 Benzphetamine
CA: [revoked] CDSA Schedule III Section 1 Subsection 18 Benzphetamine
UK: MDA Part III Class C Section 1(a) Benzphetamine
UN: Psychotropics Schedule IV Benzfetamine (Benzphetamine)
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12120 proposed to add:
(3)
1645
Chlorphentermine
CA: CDSA Schedule IV Section 3 Chlorphentermine
UK: MDA Part III Class C Section 1(a) Chlorphentermine
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12121 proposed to add:
(4)
1647
Clortermine
On 9 May 1973, 38 FR 12230 proposed to add:
Diethylpropion
US: Currently at CSA Schedule IV Section f Subsection 2 Diethylpropion
Effective 27 Nov 1981, 46 FR 52333 revoked (and renumbered subsequent entries):
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12124 proposed to add:
Mazindol
US: Currently at CSA Schedule IV Section f Subsection 5 Mazindol
Effective 15 Jun 1973, 38 FR 15719 added:
On 9 May 1973, 38 FR 12126 proposed to add:
(5)
1615
Phendimetrazine
CA: CDSA Schedule IV Section 5 Phendimetrazine
UK: MDA Part III Class C Section 1(a) Phendimetrazine
UN: Psychotropics Schedule IV Phendimetrazine
On 9 May 1973, 38 FR 12127 proposed to add:
Phentermine
US: Currently at CSA Schedule IV Section f Subsection 9 Phentermine
Effective 13 Nov 1973, 38 FR 31310 renumbered:
(c)
Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
(1)
Any compound, mixture or preparation containing:
Effective 31 Dec 1969, replacement for:
Effective 13 Nov 1973, 38 FR 31310 added (and renumbered subsequent entries):
Any compound, mixture or preparation containing Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
(i)
2126
Amobarbital
CA: CDSA Schedule IV Section 1 Subsection 3 Amobarbital
UN: Psychotropics Schedule III Amobarbital
See also CSA Schedule II Section e Subsection 1 Amobarbital and Schedule III Section c Subsection 2 Item i Amobarbital
(ii)
2316
Secobarbital
CA: CDSA Schedule IV Section 1 Subsection 24 Secobarbital
UN: Psychotropics Schedule II Secobarbital
See also CSA Schedule II Section e Subsection 5 Secobarbital and Schedule III Section c Subsection 2 Item ii Secobarbital
⇒
PubChem: 5193; ChemSpider: 5005; Bluelight: Secobarbital bioavailability; Drugs Forum: Secobarbital; Erowid: Barbiturates; Wikipedia: Secobarbital
(iii)
2271
Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
See also CSA Schedule II Section e Subsection 3 Pentobarbital and Schedule III Section c Subsection 2 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital(2)
Any suppository dosage form containing:
Effective 31 Dec 1969, replacement for:
Effective 13 Nov 1973, 38 FR 31310 added (and renumbered subsequent entries):
Any suppository dosage form containing containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
(i)
2126
Amobarbital
CA: CDSA Schedule IV Section 1 Subsection 3 Amobarbital
UN: Psychotropics Schedule III Amobarbital
See also CSA Schedule II Section e Subsection 1 Amobarbital and Schedule III Section c Subsection 1 Item i Amobarbital
(ii)
2316
Secobarbital
CA: CDSA Schedule IV Section 1 Subsection 24 Secobarbital
UN: Psychotropics Schedule II Secobarbital
See also CSA Schedule II Section e Subsection 5 Secobarbital and Schedule III Section c Subsection 1 Item ii Secobarbital
⇒
PubChem: 5193; ChemSpider: 5005; Bluelight: Secobarbital bioavailability; Drugs Forum: Secobarbital; Erowid: Barbiturates; Wikipedia: Secobarbital
(iii)
2271
Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
CA: CDSA Schedule IV Section 1 Subsection 20 Pentobarbital
UN: Psychotropics Schedule III Pentobarbital
See also CSA Schedule II Section e Subsection 3 Pentobarbital and Schedule III Section c Subsection 1 Item iii Pentobarbital
⇒
PubChem: 4737; ChemSpider: 4575; Bluelight: Pentobarbital; Drugs Forum: Pentobarbital; Erowid: Barbiturates; Wikipedia: Pentobarbital
(3)
2100
Any substance which contains any quantity of a derivative of Barbituric acid or any salt thereof
Effective 13 Nov 1973, 38 FR 31310 replacement for:
Any substance which contains any quantity of a derivative of Barbituric acid, or any salt of a derivative of Barbituric acid.
CA: CDSA Schedule IV Section 1 Subsection 6 Barbituric acid
Effective 28 Sep 2006, 71 FR 51115 added (and renumbered subsequent entries):
On 29 Aug 2005, 70 FR 50996 extended the comment period of the earlier proposal to 28 Sept 2005 from 29 Aug 2005
On 29 Jul 2005, 70 FR 43809 proposed to add (and to renumber subsequent entries):
(5)
2020
Embutramide
Effective 21 Mar 1991, 56 FR 11930 revoked (and renumbered subsequent entries):
2550
Glutethimide
US: Currently at CSA Schedule II Section e Subsection 2 Glutethimide
Effective 3 Apr 2000, 65 FR 17440 corrected an error in amendatory instruction 3 of 68 FR 13235
Effective 13 Mar 2000, 65 FR 13235 added (and renumbered subsequent entries):
(6)
2012
Any drug product containing Gamma-hydroxybutyric acid (GHB; Gamma-hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic acid; Sodium oxybate; Sodium oxybutyrate), including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act
CA: CDSA Schedule I Section 21 4-Hydroxybutanoic acid
CA: [revoked] CDSA Schedule III Section 26 4-Hydroxybutanoic acid
UK: MDA Part III Class C Section 1(a) 4-Hydroxy-n-butyric acid
UN: Psychotropics Schedule II GHB
UN: [revoked] Psychotropics Schedule IV GHB
See also CSA Schedule I Section e Subsection 1 Gamma-hydroxybutyric acid
⇒
PubChem: 10413; ChemSpider: 9984; Drugs Forum: GHB; Erowid: GHB; Wikipedia: gamma-Hydroxybutyric acid
Effective 12 Aug 1999, 64 FR 37673 added:
On 9 Apr 1999, 64 FR 17299 proposed to add:
(7)
7285
Ketamine ((±)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone), its salts, isomers, and salts of isomers
(8)
7300
Lysergic acid
CA: CDSA Schedule VI Part 1 Subsection 8 Lysergic acid
EU: Drug precursors Annex I Category 1 Lysergic acid
UK: MDA Drug precursors Annex I Category 1 Lysergic acid
UN: Precursors Table I Lysergic acid
(10)
2575
Methyprylon
CA: CDSA Schedule IV Section 17 Methyprylon
UK: MDA Part III Class C Section 1(a) Methyprylone
UN: Psychotropics Schedule IV Methyprylon
Effective 14 Mar 1977, 42 FR 8636 revoked (and renumbered subsequent entries):
7471
Phencyclidine
US: Currently at CSA Schedule II Section e Subsection 4 Phencyclidine
Effective 2 Dec 2013, 78 FR 72013 added (and renumbered subsequent entries):
On 22 Oct 2013, 78 FR 62500 proposed to add (and to renumber subsequent entries):
(11)
2261
Perampanel, and its salts, isomers, and salts of isomers
Tiletamine
Zolazepam
Effective 20 Feb 1987, 52 FR 2221 added:
(15)
7295
Tiletamine (2-(Ethylamino)-2-(2-thienyl)cyclohexanone) and Zolazepam (4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e][1,4]diazepin-7(1H)-one; Flupyrazapon) or any salt thereof
Some trade or other names for a Tiletamine-Zolazepam combination product: Telazol
⇒
PubChem: 26533; ChemSpider: 24714; Bluelight: Tiletamine; Drugs Forum: Tiletamine; Erowid: Tiletamine; Wikipedia: Tiletamine
(e)
Narcotic Drugs. Unless specifically excepted or unless listed in another schedule:
Effective 7 Oct 2002, 67 FR 62354 replacement for:
On 21 Mar 2002, 67 FR 13114 proposed replacement for:
Narcotic Drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
Effective 7 Oct 2002, 67 FR 62354 added (and renumbered subsequent entries):
On 21 Mar 2002, 67 FR 13114 proposed to add (and to renumber subsequent entries):
(1)
Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
(i)
9803
Not more than 1.8 grams of Codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of Opium
See also CSA Schedule II Section b Subsection 1 Item i Codeine, Schedule III Section e Subsection 1 Item ii Codeine and Schedule V Section c Subsection 1 Codeine
See also CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item v Opium and Schedule V Section c Subsection 5 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
(ii)
9804
Not more than 1.8 grams of Codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
Effective 6 Oct 2014, 79 FR 49661 revoked (and renumbered subsequent entries):
On 27 Feb 2014, 79 FR 11037 proposed to revoke (and to renumber subsequent entries:)
9805
Not more than 300 milligrams of Dihydrocodeinone (Hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of Opium
CA: CDSA Schedule I Section 1 Subsection 15 Hydrocodone
UK: MDA Part I Class A Section 1(a) Hydrocodone
UN: Narcotics Part 1 Section 1 Hydrocodone
⇒
PubChem: 5284569; ChemSpider: 4447623; Drugs Forum: Hydrocodone; Erowid: Hydrocodone; Wikipedia: Hydrocodone⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
Effective 6 Oct 2014, 79 FR 49661 revoked (and renumbered subsequent entries):
On 27 Feb 2014, 79 FR 11037 proposed to revoke (and to renumber subsequent entries:)
9806
Not more than 300 milligrams of Dihydrocodeinone (Hydrocodone) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 15 Hydrocodone
UK: MDA Part I Class A Section 1(a) Hydrocodone
UN: Narcotics Part 1 Section 1 Hydrocodone
⇒
PubChem: 5284569; ChemSpider: 4447623; Drugs Forum: Hydrocodone; Erowid: Hydrocodone; Wikipedia: Hydrocodone
(iii)
9807
Not more than 1.8 grams of Dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 11 Dihydrocodeine
UK: MDA Part II Class B Section 1(a) Dihydrocodeine
UN: Narcotics Part 1 Section 2 Dihydrocodeine and Part 2 Section 1 Dihydrocodeine
See also CSA Schedule II Section c Subsection 7 Dihydrocodeine and Schedule V Section c Subsection 2 Dihydrocodeine
(iv)
9808
Not more than 300 milligrams of Ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
CA: CDSA Schedule I Section 1 Subsection 13 Ethylmorphine
UK: MDA Part II Class B Section 1(a) Ethylmorphine
UN: Narcotics Part 1 Section 2 Ethylmorphine and Part 2 Section 1 Ethylmorphine
See also CSA Schedule II Section b Subsection 1 Item iii Ethylmorphine and Schedule V Section c Subsection 3 Ethylmorphine
(v)
9809
Not more than 500 milligrams of Opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
See also CSA Schedule II Section b Subsection 1 Item xvi Raw opium, Schedule III Section e Subsection 1 Item i Opium and Schedule V Section c Subsection 5 Opium
⇒
PubChem: 167253 202889 202890 17397953 17397584 3842991 202886 202888 413265 3730541; Drugs Forum: Opium; Wikipedia: Opium
(vi)
9810
Not more than 50 milligrams of Morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts
Effective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(2)
Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts as set forth below:
Effective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(i)
9064
Buprenorphine
CA: CDSA Schedule I Section 10 Subsection 1 Buprenorphine
UK: MDA Part III Class C Section 1(a) Buprenorphine
UN: Psychotropics Schedule III Buprenorphine
⇒
PubChem: 40400 644073; ChemSpider: 559124; Bluelight: Buprenorphine; Drugs Forum: Buprenorphine; Erowid: Buprenorphine; Wikipedia: BuprenorphineEffective 7 Oct 2002, 67 FR 62354 added:
On 21 Mar 2002, 67 FR 13114 proposed to add:
(ii)
(f)
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation:
Readers wanting to explore the intricacies of steroid nomenclature may find this steroid crib sheet useful.
(1)
4000
Anabolic steroids (see §1300.01 of this chapter)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Anabolic Steroids
From 21 CFR 1300.01 Definitions relating to controlled substances
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 27 Jan 2012, 77 FR 4228 replacement for:
[From 21 CFR 1300.01 Definitions relating to controlled substances]
…(4) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone), and includes:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
[From 21 CFR 1308.02 Definitions]
…(b) The term anabolic steroid means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins and corticosteroids) that promotes muscle growth, and includes:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(1)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(2)
3α,17β-Dihydroxy-5α-androstane
UK: MDA Part III Class C Section 1(b) 5α-Androstane-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(3)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(4)
1-Androstenediol (3β,17β-Dihydroxy-5α-androst-1-ene)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(5)
1-Androstenediol (3α,17β-Dihydroxy-5α-androst-1-ene)
UK: MDA Part III Class C Section 1(b) 1-Androstenediol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(6)
4-Androstenediol (3β,17β-Dihydroxyandrost-4-ene)
UK: MDA Part III Class C Section 1(b) Androst-4-ene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(7)
5-Androstenediol (3β,17β-Dihydroxyandrost-5-ene)
CA: CDSA Schedule IV Section 23 Subsection 3 Androstenediol
UK: MDA Part III Class C Section 1(b) 5-Androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(8)
1-Androstenedione ([5α]-Androst-1-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 1-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(9)
4-Androstenedione (Androst-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 4-Androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(10)
5-Androstenedione (Androst-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 5-Androstenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(11)
Bolasterone (7α,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 5 Bolasterone
UK: MDA Part III Class C Section 1(b) Bolasterone
(12)
Boldenone (17β-Hydroxyandrost-1,4-diene-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Boldenone (17β-Hydroxyandrost-1,4,-diene-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Boldenone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(13)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(14)
Calusterone (7β,17α-Dimethyl-17β-hydroxyandrost-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 9 Calusterone
UK: MDA Part III Class C Section 1(b) Calusterone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Chlorotestosterone (4-Chlortestosterone)
Chlorotestosterone is a synonym for Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(15)
Clostebol (4-Chloro-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Clostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(16)
Dehydrochloromethyltestosterone (4-Chloro-17β-hydroxy-17α-methylandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dehydrochlormethyltestosterone
UK: MDA Part III Class C Section 1(b) 4-Chloromethandienone
⇒
PubChem: 16395944; ChemSpider: 88972; Erowid: Steroids; Wikipedia: 4-Chlorodehydromethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(17)
Desoxymethyltestosterone (17α-Methyl-5α-androst-2-en-17β-ol; Madol)
UK: MDA Part III Class C Section 1(b) Desoxymethyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(18)
Δ1-Dihydrotestosterone (1-Testosterone; 17β-Hydroxy-5α-androst-1-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(19)
4-Dihydrotestosterone (17β-Hydroxyandrostan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Dihydrotestosterone (4-Dihydrotestosterone)
CA: CDSA Schedule IV Section 23 Subsection 2 Androstanolone
UK: MDA Part III Class C Section 1(b) Stanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(20)
Drostanolone (17β-Hydroxy-2α-methyl-5α-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Drostanolone
CA: CDSA Schedule IV Section 23 Subsection 11 Drostanolone
UK: MDA Part III Class C Section 1(b) Drostanolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(21)
Ethylestrenol (17α-Ethyl-17β-hydroxyestr-4-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Ethylestrenol
CA: CDSA Schedule IV Section 23 Subsection 14 Ethylestrenol
UK: MDA Part III Class C Section 1(b) Ethyloestrenol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(22)
Fluoxymesterone (9-Fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Fluoxymesterone
CA: CDSA Schedule IV Section 23 Subsection 16 Fluoxymesterone
UK: MDA Part III Class C Section 1(b) Fluoxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(23)
Formebolone (2-Formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Formebulone (Formebolone)
CA: CDSA Schedule IV Section 23 Subsection 17 Formebolone
UK: MDA Part III Class C Section 1(b) Formebolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(24)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(25)
13β-Ethyl-17β-hydroxygon-4-en-3-one
Effective 13 Oct 2006, 71 FR 60426 replacement for:
13β-Ethyl-17α-hydroxygon-4-en-3-one
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(26)
4-Hydroxytestosterone (4,17β-Dihydroxyandrost-4-en-3-one)
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(27)
4-Hydroxy-19-nortestosterone (4,17β-Dihydroxy-estr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 15 4-Hydroxy-19-nortestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(28)
Mestanolone (17α-Methyl-17β-hydroxy-5α-androstan-3-one)
UK: MDA Part III Class C Section 1(b) Mestanolone
(29)
Mesterolone (1α-Methyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Mesterolone (1αMethyl-17β-hydroxy-[5α]-androstan-3-one)
Effective 27 Feb 1991, 56 FR 5753 added:
Mesterolone
CA: CDSA Schedule IV Section 23 Subsection 21 Mesterolone
UK: MDA Part III Class C Section 1(b) Mesterolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(30)
Methandienone (17α-Methyl-17β-hydroxyandrost-1,4-dien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandienone
CA: CDSA Schedule IV Section 23 Subsection 22 Metandienone
UK: MDA Part III Class C Section 1(b) Methandienone
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandranone
Source: Shulgin, Alexander T. Controlled Substances: Chemical & Legal Guide to Federal Drugs Laws (2nd edition). Ronin Publishing Inc., Berkeley, 1992
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(31)
Methandriol (17α-Methyl-3β,17β-dihydroxyandrost-5-ene)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandriol
CA: CDSA Schedule IV Section 23 Subsection 24 Methandriol
UK: MDA Part III Class C Section 1(b) Methandriol
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Methandrostenolone
Methandrostenolone is a synonym for Methandienone
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(32)
Methasterone (2α,17α-Dimethyl-5α-androstan-17β-ol-3-one)
See also CSA Schedule III Section f Subsection 1 Item 73 2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(33)
Methenolone (1-Methyl-17β-hydroxy-5α-androst-1-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methenolone
CA: CDSA Schedule IV Section 23 Subsection 23 Metenolone
UK: MDA Part III Class C Section 1(b) Methenolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(34)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(35)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(36)
17α-Methyl-3β,17β-dihydroxyandrost-4-ene
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(37)
17α-Methyl-4-hydroxynandrolone (17α-Methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(38)
Methyldienolone (17α-Methyl-17β-hydroxyestra-4,9(10)-dien-3-one)
(39)
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9,11-trien-3-one)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
Methyltrienolone (17α-Methyl-17β-hydroxyestra-4,9-11-trien-3-one)
CA: CDSA Schedule IV Section 23 Subsection 26 Metribolone
UK: MDA Part III Class C Section 1(b) Metribolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(40)
Methyltestosterone (17α-Methyl-17β-hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Methyltestosterone
CA: CDSA Schedule IV Section 23 Subsection 25 Methyltestosterone
UK: MDA Part III Class C Section 1(b) Methyltestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(41)
Mibolerone (7α,17α-Dimethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Mibolerone
CA: CDSA Schedule IV Section 23 Subsection 27 Mibolerone
UK: MDA Part III Class C Section 1(b) Mibolerone
(42)
17α-Methyl-Δ1-dihydrotestosterone (17β-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
Effective 27 Jan 2012, 77 FR 4228 replacement for:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
17α-Methyl-Δ1-dihydrotestosterone (17bβ-Hydroxy-17α-methyl-5α-androst-1-en-3-one; 17α-Methyl-1-testosterone)
⇒
PubChem: 7092657; ChemSpider: 5442174; Bluelight: Methyl-1-Testosterone; Drugs Forum: M-1-T; Erowid: Steroids; Wikipedia: Methyl-1-testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(43)
Nandrolone (17β-Hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Nandrolone
CA: CDSA Schedule IV Section 23 Subsection 28 Nandrolone
UK: MDA Part III Class C Section 1(b) Nandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(44)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(45)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(46)
19-Nor-5-androstenediol (3β,17β-Dihydroxyestr-5-ene)
UK: MDA Part III Class C Section 1(b) 19-Nor-5-androstene-3,17-diol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(47)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 4 Jan 2010, 74 FR 63603 added (and renumbered subsequent entries):
On 25 Apr 2008, 73 FR 22294 proposed to add (and to renumber subsequent entries):
(48)
19-Nor-4,9(10)-androstadienedione (Estra-4,9(10)-diene-3,17-dione)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(49)
19-Nor-4-androstenedione (Estr-4-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Nor-4-androstene-3,17-dione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(50)
19-Nor-5-androstenedione (Estr-5-en-3,17-dione)
UK: MDA Part III Class C Section 1(b) 19-Norandrostenedione
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(51)
Norbolethone (13β,17α-Diethyl-17β-hydroxygon-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 29 Norboletone
UK: MDA Part III Class C Section 1(b) Norboletone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(52)
Norclostebol (4-Chloro-17β-hydroxyestr-4-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 30 Norclostebol
UK: MDA Part III Class C Section 1(b) Norclostebol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(53)
Norethandrolone (17α-Ethyl-17β-hydroxyestr-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Norethandrolone
CA: CDSA Schedule IV Section 23 Subsection 31 Norethandrolone
UK: MDA Part III Class C Section 1(b) Norethandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(54)
Normethandrolone (17α-Methyl-17β-hydroxyestr-4-en-3-one)
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(55)
Oxandrolone (17α-Methyl-17β-hydroxy-2-oxa-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxandrolone
CA: CDSA Schedule IV Section 23 Subsection 33 Oxandrolone
UK: MDA Part III Class C Section 1(b) Oxandrolone
⇒
PubChem: 5878; ChemSpider: 5667; Bluelight: Oxandrolone; Drugs Forum: Oxandrolone; Erowid: Steroids; Wikipedia: Oxandrolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(56)
Oxymesterone (17α-Methyl-4,17β-dihydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymesterone
CA: CDSA Schedule IV Section 23 Subsection 34 Oxymesterone
UK: MDA Part III Class C Section 1(b) Oxymesterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(57)
Oxymetholone (17α-Methyl-2-hydroxymethylene-17β-hydroxy-[5α]-androstan-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Oxymetholone
CA: CDSA Schedule IV Section 23 Subsection 35 Oxymetholone
UK: MDA Part III Class C Section 1(b) Oxymetholone
⇒
PubChem: 3032303; ChemSpider: 4444502; Bluelight: Oxymetholone; Erowid: Steroids; Wikipedia: Oxymetholone
Prostanozol
Prostanozol, O-tetrahydropyran-2-yl
Effective 29 Aug 2012, 77 FR 44456 added (and renumbered subsequent entries):
On 23 Nov 2011, 76 FR 72355 proposed to add (and to renumber subsequent entries):
(58)
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole)
[There is much confusion surrounding the name Prostanozol. The culprit seems to be the World Anti-Doping Agency (WADA), which every year updates their list of Prohibited Substances.
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
For 2009 (and later) it reads:
Prostanozol (17β-Hydroxy-5α-androstano[3,2-c]pyrazole), depicted at left, above.
For 2008 (and earlier) it reads:
Prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol), depicted at left, below.
Given these names describe distinctly different substances WADA’s explanation—“The nomenclature of Prostanozol has been changed to better follow the International Union of Pure and Applied Chemistry (IUPAC) rules”—has a certain… CYA quality. Not very helpful WADA. Definitely not very sporting.]
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 89 [3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol, O-tetrahydropyran-2-yl
Effective 17 Jan 2006, 70 FR 74653 revoked:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanolone
Stanolone is a synonym for 4-Dihydrotestosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(59)
Stanozolol (17α-Methyl-17β-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 13 Oct 2006, 71 FR 60426 replacement for:
Stanozolol (17α-Methyl-17α-hydroxy-[5α]-androst-2-eno[3,2-c]pyrazole)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Stanozolol
CA: CDSA Schedule IV Section 23 Subsection 38 Stanozolol
UK: MDA Part III Class C Section 1(b) Stanozolol
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(60)
Stenbolone (17β-Hydroxy-2-methyl-[5α]-androst-1-en-3-one)
CA: CDSA Schedule IV Section 23 Subsection 39 Stenbolone
UK: MDA Part III Class C Section 1(b) Stenbolone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(61)
Testolactone (13-Hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testolactone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(62)
Testosterone (17β-Hydroxyandrost-4-en-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Testosterone
CA: CDSA Schedule IV Section 23 Subsection 40 Testosterone
UK: MDA Part III Class C Section 1(b) Testosterone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
Effective 17 Jan 2006, 70 FR 74653 added (and renumbered subsequent entries):
(63)
Tetrahydrogestrinone (13β,17α-Diethyl-17β-hydroxygon-4,9,11-trien-3-one)
UK: MDA Part III Class C Section 1(b) Tetrahydrogestrinone
⇒
PubChem: 25320811 6857686; ChemSpider: 5257020; Bluelight: Tetrahydrogestrinone; Erowid: Steroids; Wikipedia: Tetrahydrogestrinone
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(64)
Trenbolone (17β-Hydroxyestr-4,9,11-trien-3-one)
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Trenbolone and
[With thanks to Jan of Palo Alto for reporting an error in the structural diagram shown previously for this substance.]
CA: CDSA Schedule IV Section 23 Subsection 43 Trenbolone
UK: MDA Part III Class C Section 1(b) Trenbolone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(65)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(67)
6-Bromo-androsta-1,4-diene-3,17-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(68)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 72 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(69)
4-Chloro-17α-methyl-androst-4-ene-3β,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(70)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(71)
4-Chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(72)
4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
See also CSA Schedule III Section f Subsection 1 Item 68 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(73)
2α,17α-Dimethyl-17β-hydroxy-5α-androstan-3-one
See also CSA Schedule III Section f Subsection 1 Item 32 Methasterone
⇒
PubChem: 237186; ChemSpider: 207079; Bluelight: Superdrol; Erowid: Steroids; Wikipedia: Methasterone
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(74)
2α,17α-Dimethyl-17β-hydroxy-5β-androstan-3-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(75)
![3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]-Furazan-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(76)
[3,2-c]-Furazan-5α-androstan-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(77)
3β-Hydroxy-estra-4,9,11-trien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(78)
17α-Methyl-androst-2-ene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(79)
17α-Methyl-androsta-1,4-diene-3,17β-diol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(80)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(81)
18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(82)
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(83)
17α-Methyl-androstan-3-hydroxyimine-17β-ol
![3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole](data:image/png;base64,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 "Click for a 3D rendering of 17β-Hydroxy-androstano[2,3-d]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(85)
17β-Hydroxy-androstano[2,3-d]isoxazole
![3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole](data:image/png;base64,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 "Click for a 3D rendering of 17β-Hydroxy-androstano[3,2-c]isoxazole")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(86)
17β-Hydroxy-androstano[3,2-c]isoxazole
![3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of 4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(87)
4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5α-androstan-17β-ol [sic]
![3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol](data:image/png;base64,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 "Click for a 3D rendering of [3,2-c]Pyrazole-androst-4-en-17β-ol")
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(88)
[3,2-c]Pyrazole-androst-4-en-17β-ol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. added:
(89)
[3,2-c]Pyrazole-5α-androstan-17β-ol
UK: MDA Part III Class C Section 1(b) Prostanozol
See also CSA Schedule III Section f Subsection 1 Item 58 Prostanozol
Effective 18 Dec 2014, H.R. 4771, 113 Cong., 2nd Sess. renumbered:
Effective 27 Jan 2012, 77 FR 4228 renumbered:
(90)
Any salt, ester, or ether of a drug or substance described in this paragraph. Except such term does not include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, the person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
Effective 17 Jan 2006, 70 FR 74653 replacement for:
Effective 27 Feb 1991, 56 FR 5753 added:
Any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth. Except such term does not include an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this paragraph.
Effective 2 Jul 1999, 64 FR 35928 added:
On 5 Nov 1998, 63 FR 59751 proposed to add:
(g)
Hallucinogenic substances.
Effective 2 Jul 1999, 64 FR 35928 added:
On 5 Nov 1998, 63 FR 59751 proposed to add:
(1)
7369
Dronabinol ((6aR-trans)-6a,7,8,10a-Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; (–)-Delta-9-(trans)-tetrahydrocannabinol) (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved product
UN: Psychotropics Schedule II Dronabinol (delta-9-Tetrahydrocannabinol)
11 March 2016 · 
· Isomer Design
· Isomer Design